Medtronic completes USD 650 million acquisition of SPR Therapeutics

• Medtronic completed its acquisition of SPR Therapeutics for USD 650 million in upfront cash.
• Deal adds SPR’s FDA-cleared SPRINT PNS System, a 60-day percutaneous peripheral nerve stimulation therapy that avoids a permanent implant.
• Medtronic expects the transaction to be minimally dilutive to adjusted EPS in FY27, turning neutral to accretive thereafter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief via PR Newswire (Ref. ID: CG05960) on July 16, 2026, and is solely responsible for the information contained therein.